Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Inflammation Research
Erschienen in: Inflammation Research 7/2010

01.07.2010 | Original Research Paper

Associations between plasma insulin-like growth factor-I and the markers of inflammation interleukin 6, C-reactive protein and YKL-40 in an elderly background population

verfasst von: Mikkel Andreassen, Ilan Raymond, Per Hildebrandt, Caroline Kistorp, Camilla Rathcke, Henrik Vestergaard, Jens Faber, Lars Østergaard Kristensen

Erschienen in: Inflammation Research | Ausgabe 7/2010

Einloggen, um Zugang zu erhalten

Abstract

Background and objective

The objective of the present study was to test the hypothesis that circulating levels of insulin-like growth factor-I (IGF-I) are inversely associated with inflammatory processes in an elderly background population.

Patients and design

We conducted a population-based study comprising 629 individuals, aged 50–89 years. Associations between plasma IGF-I versus interleukin 6 (IL-6) and the acute phase proteins high sensitive C-reactive protein (hsCRP) and YKL-40 were evaluated by linear regression analyses. Subsequently, the population was dichotomised at a CRP level of 3.0 mg/L and the associations were re-evaluated in the two subgroups.

Results

Adjusted for confounding variables, plasma IGF-I was inversely related to IL-6, hsCRP and YKL-40 (all P < 0.001). The strongest association was found for YKL-40 with a 34% reduction in YKL-40 per twofold increase in IGF-I. A significant inverse association between IGF-I and all markers of inflammation persisted in individuals with hsCRP below 3.0 mg/L whereas only YKL-40 was significantly associated with IGF-I in individuals with hsCRP above 3.0 mg/L.

Conclusions

The data support the hypothesis of an inverse association between GH/IGF-I signalling and inflammation, and suggest that the relationship between the IGF-I and inflammation might be more predominant in healthy individuals with a low inflammatory activity.
Literatur
1.
Juul A. Serum levels of insulin-like growth factor I and its binding proteins in health and disease. Growth Horm IGF Res. 2003;13(4):113–70.CrossRefPubMed
2.
Gouin JP, Hantsoo L, Kiecolt-Glaser JK. Immune dysregulation and chronic stress among older adults: a review. Neuroimmunomodulation. 2008;15(4–6):251–9.CrossRefPubMed
3.
Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Ann Rev Med. 2000;51:245–70.CrossRefPubMed
4.
Flores-Morales A, Greenhalgh CJ, Norstedt G, Rico-Bautista E. Negative regulation of growth hormone receptor signaling. Mol Endocrinol. 2006;20(2):241–53.CrossRefPubMed
5.
Wang P, Li N, Li JS, Li WQ. The role of endotoxin, TNF-alpha, and IL-6 in inducing the state of growth hormone insensitivity. World J Gastroenterol. 2002;8(3):531–6.PubMed
6.
Lang CH, Hong-Brown L, Frost RA. Cytokine inhibition of JAK-STAT signaling: a new mechanism of growth hormone resistance. Pediatr Nephrol. 2005;20(3):306–12.CrossRefPubMed
7.
Denson LA, Held MA, Menon RK, Frank SJ, Parlow AF, Arnold DL. Interleukin-6 inhibits hepatic growth hormone signaling via upregulation of Cis and Socs-3. Am J Physiol Gastrointest Liver Physiol. 2003;284(4):G646–54.PubMed
8.
Barbieri M, Ferrucci L, Ragno E, Corsi A, Bandinelli S, Bonafe M, et al. Chronic inflammation and the effect of IGF-I on muscle strength and power in older persons. Am J Physiol Endocrinol Metab. 2003;284(3):E481–7.PubMed
9.
Rajpathak SN, McGinn AP, Strickler HD, Rohan TE, Pollak M, Cappola AR, et al. Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res. 2008;18(2):166–73.CrossRefPubMed
10.
Cappola AR, Xue QL, Ferrucci L, Guralnik JM, Volpato S, Fried LP. Insulin-like growth factor I and interleukin-6 contribute synergistically to disability and mortality in older women. J Clin Endocrinol Metab. 2003;88(5):2019–25.CrossRefPubMed
11.
Leng SX, Cappola AR, Andersen RE, Blackman MR, Koenig K, Blair M, et al. Serum levels of insulin-like growth factor-I (IGF-I) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty. Aging Clin Exp Res. 2004;16(2):153–7.PubMed
12.
Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull. 2006;53(2):172–209.PubMed
13.
Raymond I, Pedersen F, Busch-Sorensen M, Green A, Hildebrandt P. The Frederiksberg Heart Failure Study: Rationale, design and methodology, with special emphasis on the sampling procedure for the study population and its comparison to the background population. Heart Drug 2002;(2):167–74.
14.
Raymond I, Pedersen F, Steensgaard-Hansen F, Green A, Busch-Sorensen M, Tuxen C, et al. Prevalence of impaired left ventricular systolic function and heart failure in a middle aged and elderly urban population segment of Copenhagen. Heart. 2003;89(12):1422–9.CrossRefPubMed
15.
Kistorp C, Raymond I, Pedersen F, Gustafsson F, Faber J, Hildebrandt P. N-terminal pro-brain natriuretic peptide, C-reactive protein, and urinary albumin levels as predictors of mortality and cardiovascular events in older adults. JAMA. 2005;293(13):1609–16.CrossRefPubMed
16.
Andreassen M, Raymond I, Kistorp C, Hildebrandt P, Faber J, Kristensen LO. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol. 2009;160(1):25–31.CrossRefPubMed
17.
Rathcke CN, Raymond I, Kistorp C, Hildebrandt P, Faber J, Vestergaard H. Low grade inflammation as measured by levels of YKL-40: association with an increased overall and cardiovascular mortality rate in an elderly population. Int J Cardiol. 2009 [Epub ahead of print].
18.
Yu H, Mistry J, Nicar MJ, Khosravi MJ, Diamandis A, van DJ, et al. Insulin-like growth factors (IGF-I, free IGF-I and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation. J Clin Lab Anal. 1999;13(4):166–72.CrossRefPubMed
19.
Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO III, Criqui M, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107(3):499–511.CrossRefPubMed
20.
Lemmey A, Maddison P, Breslin A, Cassar P, Hasso N, McCann R, et al. Association between insulin-like growth factor status and physical activity levels in rheumatoid arthritis. J Rheumatol. 2001;28(1):29–34.PubMed
21.
Picardi A, Gentilucci UV, Zardi EM, Caccavo D, Petitti T, Manfrini S, et al. TNF-alpha and growth hormone resistance in patients with chronic liver disease. J Interferon Cytokine Res. 2003;23(5):229–35.CrossRefPubMed
22.
Eivindson M, Nielsen JN, Gronbaek H, Flyvbjerg A, Hey H. The insulin-like growth factor system and markers of inflammation in adult patients with inflammatory bowel disease. Horm Res. 2005;64(1):9–15.CrossRefPubMed
23.
Fernihough JK, Billingham ME, Cwyfan-Hughes S, Holly JM. Local disruption of the insulin-like growth factor system in the arthritic joint. Arthritis Rheum. 1996;39(9):1556–65.CrossRefPubMed
24.
Neidel J. Changes in systemic levels of insulin-like growth factors and their binding proteins in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2001;19(1):81–4.PubMed
25.
Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, et al. Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant. J Clin Endocrinol Metab. 2002;87(4):1692–9.CrossRefPubMed
26.
Sesmilo G, Miller KK, Hayden D, Klibanski A. Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab. 2001;86(12):5774–81.CrossRefPubMed
27.
Andreassen M, Vestergaard H, Kristensen LO. Concentrations of the acute phase reactants high-sensitive C-reactive protein and YKL-40 and of interleukin-6 before and after treatment in patients with acromegaly and growth hormone deficiency. Clin Endocrinol (Oxf). 2007;67(6):909–16.CrossRef
28.
Colao A, Marzullo P, Di SC, Lombardi G. Growth hormone and the heart. Clin Endocrinol (Oxf). 2001;54(2):137–54.CrossRef
29.
Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135–43.CrossRefPubMed
30.
Bengtsson BA, Brummer RJ, Bosaeus I. Growth hormone and body composition. Horm Res. 1990;33(Suppl 4):19–24.CrossRefPubMed
31.
Werner H, Bruchim I. The insulin-like growth factor-I receptor as an oncogene. Arch Physiol Biochem. 2009;115(2):58–71.PubMed
32.
Moller J. Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects. Growth Horm IGF Res. 2003;13(23):55–74.CrossRefPubMed
33.
Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152–77.CrossRefPubMed
34.
Waters MJ, Shang CA, Behncken SN, Tam SP, Li H, Shen B, et al. Growth hormone as a cytokine. Clin Exp Pharmacol Physiol. 1999;26(10):760–4.CrossRefPubMed
35.
Auernhammer CJ, Melmed S. The central role of SOCS-3 in integrating the neuro-immunoendocrine interface. J Clin Invest. 2001;108(12):1735–40.PubMed
36.
De CF, Gaufillier S, Bonnaud A, Sabatini M, Lesur C, Pastoureau P. YKL-40 (cartilage gp-39) induces proliferative events in cultured chondrocytes and synoviocytes and increases glycosaminoglycan synthesis in chondrocytes. Biochem Biophys Res Commun. 2001;285(4):926–31.CrossRef
37.
Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J. 2002;365(Pt 1):119–26.CrossRefPubMed
38.
Kawamura K, Shibata T, Saget O, Peel D, Bryant PJ. A new family of growth factors produced by the fat body and active on Drosophila imaginal disc cells. Development. 1999;126(2):211–9.PubMed
39.
Johansen JS, Hoyer PE, Larsen LA, Price PA, Mollgard K. YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem. 2007;55(12):1213–28.CrossRefPubMed
40.
Kokkoris P, Pi-Sunyer FX. Obesity and endocrine disease. Endocrinol Metab Clin North Am. 2003;32(4):895–914.CrossRefPubMed
41.
Frystyk J, Brick DJ, Gerweck AV, Utz AL, Miller KK. Bioactive IGF-I in obesity. J Clin Endocrinol Metab. 2009;94:3093–7.
Metadaten
Titel
Associations between plasma insulin-like growth factor-I and the markers of inflammation interleukin 6, C-reactive protein and YKL-40 in an elderly background population
verfasst von
Mikkel Andreassen
Ilan Raymond
Per Hildebrandt
Caroline Kistorp
Camilla Rathcke
Henrik Vestergaard
Jens Faber
Lars Østergaard Kristensen
Publikationsdatum
01.07.2010
Verlag
SP Birkhäuser Verlag Basel
Erschienen in
Inflammation Research / Ausgabe 7/2010
Print ISSN: 1023-3830
Elektronische ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-009-0154-z

Weitere Artikel der Ausgabe 7/2010

Inflammation Research 7/2010 Zur Ausgabe

Erratum

Erratum to: Early administration of propofol protects against endotoxin-induced acute lung injury in rats by inhibiting the TGF-β1-Smad2 dependent pathway

Original Research Paper

Effects of alpha 1-antitrypsin on endotoxin-induced lung inflammation in vivo

Original Research Paper

Vascular endothelial growth factor expression levels of gingiva in gingivitis and periodontitis patients with/without diabetes mellitus

Original Research Paper

Hyaluronic acid inhibits nitric oxide-induced apoptosis and dedifferentiation of articular chondrocytes in vitro

Erratum

Erratum to: Abstract supplement to the 8th World Congress on Trauma, Shock, Inflammation and Sepsis – TSIS 2010

Original Research Paper

Over-expression of caveolin-1 aggravate LPS-induced inflammatory response in AT-1 cells via up-regulation of cPLA2/p38 MAPK

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise